PRPO
$29.35
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States.
Recent News
Top Stock Reports for AbbVie, Coca-Cola & Chevron
ABBV, KO and CVX headline Zacks' top stock reports as analysts flag growth drivers, strategic moves and key headwinds shaping 2025 outlooks.
Precipio Stock Up Following Solid Q3 Earnings and Improved Cash Flow
PRPO reports strong third-quarter 2025 results with higher revenue, positive cash flow and improved margins in core divisions.
Precipio Inc (PRPO) Q3 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ...
Precipio Inc (PRPO) achieves positive adjusted EBITDA for the first time, marking a significant financial milestone amidst strategic investments and operational challenges.
The Zacks Analyst Blog Highlights HSBC, American Express, TotalEnergies, Armanino Foods of Distinction and Precipio
HSBC, American Express, TotalEnergies, Armanino Foods, and Precipio stand out in Zacks' latest research highlights.
Precipio Second Quarter 2025 Earnings: EPS: US$0.049 (vs US$0.83 loss in 2Q 2024)
NasdaqCM:PRPO 1 Year Share Price vs Fair Value Explore Precipio's Fair Values from the Community and select yours...